Mithridion raises new funds for its CNS focus, and seeks partners
This article was originally published in Scrip
Executive Summary
Mithridion Inc, a drug development company in Madison, Wisconsin focusing on serious central nervous system disorders such as Alzheimer's disease and schizophrenia, has announced that it has secured $1.25 million in new funding, and that it is seeking partners for its lead drug candidates.